InsiderPulse| Date | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-01 | Susman Robert Graham | Director | Sale | 2,502 | $27.17 | $68K | 36.4K | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Research and development | $360.9M+69.5% | $212.9M+32.9% | $160.3M+57.4% | $101.8M |
| Acquired in-process research and development | $0-100.0% | $12.5M+25.0% | $10.0M | $0 |
| General and administrative | $77.2M+34.8% | $57.3M+19.3% | $48.0M-11.4% | $54.2M |
| Total operating expenses | $438.2M+55.0% | $282.7M+29.5% | $218.3M+39.9% | $156.0M |
| Interest income | -$24.7M+0.9% | -$24.9M-229.2% | -$7.6M | — |
| Other (income) expense, net | -$471K-146.7% | $1.0M+298.4% | $253K | — |
| Loss before provision for income taxes | -$412.9M-59.6% | -$258.8M-22.7% | -$211.0M | — |
| Provision for income taxes | $891K+57.1% | $567K+6200.0% | $9K | — |
| Net loss | -$413.8M-59.6% | -$259.3M-22.9% | -$211.0M-34.6% | -$156.7M |
| Net loss per common share - basic (in dollars per share) | -$3K-45.2% | -$2K-9.9% | -$2K-19.6% | -$1K |
| Net loss per common share - diluted (in dollars per share) | -$3K-45.2% | -$2K-9.9% | -$2K-19.6% | -$1K |
| Weighted average common shares outstanding – basic (in shares) | $151.57B+9.8% | $138.10B+12.2% | $123.08B | — |
| Weighted average common shares outstanding – diluted (in shares) | $151.57B+9.8% | $138.10B+12.2% | $123.08B | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Immunovant: Best-In-Class Ambitions, Still Unproven
Amgen's Thyroid Eye Disease Data Rocks Rival Viridian, Makes It The Better Buy
IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints
Should Brepocitinib’s New Trials and Batoclimab’s Setback Require Action From Roivant Sciences (ROIV) Investors?